Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Services-Help Supply Services · market cap $426M
Research and calibrated estimates, not financial advice — verify before acting.
No upcoming catalysts in our calendar.
| Asset | Phase | Indication |
|---|---|---|
| RP101 | Phase 2 | Dry Eye Syndromes |
| Chloroprocaine HCl 2% | Phase 3 | Axillary Nerve Block |
| Chloroprocaine HCl 1% | Phase 2 | Short Duration Lower Limb Surgery Via Spinal Anaesthesia |
| rhNGF 20 µg/mL | Phase 2 | Dry Eye Syndrome |
| 30 mg Paracetamol 3% (1 mL) | Phase 2 | Pain, Postoperative |
| Paracetamol 3% | Phase 2 | Phase 1: Pain Management |
Daily closes through 2026-07-21. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.